Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can smart tech help african americans better manage diabetes?

NCT ID NCT02088658

Disease control Sponsor: State University of New York at Buffalo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a program that combines technology (like a monitoring system) with diabetes education and skills training can help African American adults with poorly controlled type 2 diabetes. About 200 participants used the system for 12 months, and researchers measured their blood sugar levels (HbA1c) at the end. The goal was to see if this approach improves diabetes management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

200 people

The number who actually took part.

Started

May 2013

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥21 years * Clinical diagnosis of T2DM and HbA1c ≥8% at the screening visit * Self-identified as AA * Subject must be willing to use the FORA monitoring system for 12 months * Subjects must be able to communicate in English * Subjects must have access to a telephone (landline for data uploads) for the study period Exclusion Criteria: * Mental confusion on interview suggesting significant dementia * Participation in other diabetes clinical trials * Alcohol or drug abuse/dependency * Active psychosis or acute mental disorder * Life expectancy \<12 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type II are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type II Diabetes mellitus, adult-onset Diabetes mellitus, non-insulin-dependent Diabetes mellitus, noninsulin dependent Diabetes mellitus, type 2

Contacts and locations

Locations

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.